Base Therapeutics
China - ShanghaiBiotechnology
Focus: Base Therapeutics is a gene-edited cell therapy company focused on oncology and immunology applications, operating from Shanghai with an early-stage pipeline in clinical development.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Open Jobs
6+6 this month
Growing — net +6 jobs in 30d
6 jobs added vs 0 removed. Steady team buildout.
Should You Work at Base Therapeutics?
AI assessmentBase Therapeutics offers early-stage scientific opportunity in a promising modality, but lack of hiring activity and early pipeline stage present significant execution and career stability risks.
Why Work Here
- Ground-floor opportunity in gene-edited cell therapies, an emerging modality with significant clinical validation potential
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1
Clinical Trials (2)
NCT06541405Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Phase 1Help build intelligence for Base Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.